MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Attitudes of Care Partners Toward Medications for Parkinson’s Disease Psychosis

    S. Mantri, S. Albert, E. Klawson, L. Alzyoud, M. Daeschler, C. Kopil, C. Marras, L. Chahine (Toronto, ON, Canada)

    Objective: To explore attitudes regarding use of medications among care partners of individuals with Parkinson’s disease psychosis. Background: Parkinson’s disease (PD) psychosis is a highly…
  • MDS Virtual Congress 2020

    Donepezil for mild cognitive impairment in Parkinson’s disease: A 48-week follow-up study

    K. Baik, S. Kim, S. Kang, Y. Sohn, P. Lee, S. Kang (Seoul, Republic of Korea)

    Objective: To investigate the efficacy of donepezil for mild cognitive impairment (MCI) in Parkinson’s disease (PD). Background: MCI is common in PD. The mechanism of…
  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Impulse Control Disorders

    A. Espay, K. Markopoulou, P. Bhargava, B. Navia (Cincinnati, OH, USA)

    Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) on impulse control disorders (ICD) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In…
  • MDS Virtual Congress 2020

    Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study

    S. Isaacson, W. Poewe, T. Simuni, O. Rosenfeld, R. Case, T. Yardeni, W. Olanow (Boca Raton, FL, USA)

    Objective: The primary objective of this long-term study was to evaluate the safety and tolerability of a 24-hour regimen and a 16-hour ‘waking day’ regimen…
  • MDS Virtual Congress 2020

    Interpretation of health-related quality of life outcomes from the EARLYSTIM Study

    P. Martinez-Martin, G. Deuschl, L. Tonder, A. Schnitzler, J.L Houeto, J. Rau, C. Schade-Brittinger, V. Stoker, M. Vidailhet, P. Krack (Madrid, Spain)

    Objective: To conduct a secondary analysis of the EARLYSTIM study1 to 1: Quantify the meaning of HRQoL outcomes and 2: Evaluate the changes of disease…
  • MDS Virtual Congress 2020

    Real Time Quality Control for Subjective Endpoints in Clinical Trials

    Y. Peng, G. Morinan, J. O'Keeffe (London, United Kingdom)

    Objective: Here we present a system which is capable of performing nearly-real time monitoring of UPDRS part-3 motor assessments using a combination of multidimensional statistics…
  • MDS Virtual Congress 2020

    Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings

    F. Stocchi, C. Olanow, E. Peckham, F. Agbo, Y. Chiu, K. Sciarappa, B. Navia (Rome, Italy)

    Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…
  • MDS Virtual Congress 2020

    Postmenopausal hormone therapy and Alzheimer’s disease, dementia, and Parkinson’s disease: A systematic review and time-response meta-analysis

    M. wu, M. Ye (Nanjing, China)

    Objective: The study aim was to determine the relation between menopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease in human subjects. Background: We…
  • MDS Virtual Congress 2020

    Combined therapy VS only levodopa therapy in a 5-years follow up cohort

    C. Borrue-Fernandez, J. Alvarez -Alberca (San Sebastian Reyes, Spain)

    Objective: Describe the frequencies of appearance of motor fluctuations, impulse control disorders, in two therapeutic regimes: combined therapy (levodopa plus an other antiparkinsonian drug) or…
  • MDS Virtual Congress 2020

    Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: A post-hoc conservative analysis

    J. Ferreira, A. Lees, G. Ebersbach, A.T Santos, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: To assess the efficacy of opicapone 50 mg (OPC 50 mg), compared with entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients recently…
  • « Previous Page
  • 1
  • …
  • 60
  • 61
  • 62
  • 63
  • 64
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • #25179 (not found)
  • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley